SuperworthAvantor EPS AVTR
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$0.84
- Latest quarter, Q2 FY26
- $0.06
- −33% on a year earlier
- Fiscal year 2025
- −$0.78
- −175% on the year before
Avantor's earnings per share was −$0.84 over the twelve months to Jun 30, 2026, down 185% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.06, down 33% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.78 | −175% |
| FY2024 | $1.04 | +117% |
| FY2023 | $0.48 | −53% |
| FY2022 | $1.02 | +19% |
| FY2021 | $0.86 | +856% |
| FY2020 | $0.09 | n/a |
| FY2019 | −$1.46 | n/a |
| FY2018 | −$2.69 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.06 | −33% | −$0.84 | |
| Q1 FY26 | $0.06 | −33% | −$0.81 | |
| Q4 FY25 | $0.08 | −89% | −$0.78 | |
| Q3 FY25 | −$1.04 | −1400% | −$0.13 | |
| Q2 FY25 | $0.09 | −36% | $0.99 | |
| Q1 FY25 | $0.09 | +0% | $1.04 | |
| Q4 FY24 | $0.73 | +387% | $1.04 | |
| Q3 FY24 | $0.08 | −50% | $0.46 | |
| Q2 FY24 | $0.14 | n/a | $0.54 | |
| Q1 FY24 | $0.09 | −50% | $0.39 | |
| Q4 FY23 | $0.15 | −29% | $0.48 | |
| Q3 FY23 | $0.16 | −36% | $0.54 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AVTRAvantor | −$0.84 | −185% a year |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| CAICaris Life Sciences | $0.37 | |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| LNTHLantheus | $4.13 | +10% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| BLLNBillionToOne | $0.65 | |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| Peer median | $6.19 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Avantor
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.